Chronic hepatitis B virus infection is difficult to cure due to the persistence of covalently closed circular DNA and viral-mediated inactivation of host immune responses. Existing nucleoside (acid) analogs or pegylated interferon therapy are difficult to achieve a high ratio of HBV surface antigen clearance. This article reviews the structure and function of HBV core protein, the classification and application prospects of core protein allosteric modulators.